Autopsy report · NCT03417024

Automated Breast Ultrasound Case Collection Registry

“Change in business strategy”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 6 months before it stopped.
• 13 participants enrolled.
• Results were posted on the registry 7 months after it ended.

Vital statistics

Status

Terminated

Sponsor

GE Healthcare

Sponsor type

Industry

Conditions

Breast Cancer

Interventions

Automated Breast Ultrasound; Digital Breast Tomosynthesis

Participants

13

Sites

1

Countries

United States

Trials that died the same way

• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (97% match in meaning)
• A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002
  “Business strategy” (86% match in meaning)
• Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease
  “Change in company strategy.” (84% match in meaning)
• Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
  “Change in strategy” (83% match in meaning)
• Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
  “Strategy Change” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.